



**VENTURA™**  
PRECISION MEDICINE

**Clinical ID:** ABC-12345

**Cellworks ID:** 444444

**Ref Physician:** Dr.John

**Biopsy Sequence:** 1

**Gender/Age:** - / -

**Date of Report:** 06th Aug 2018

**Indication: Myelodysplastic Syndrome(MDS)**

1. Personalized Therapy Recommendation(s)

Drug Combination(s)
AZACITIDINE and CYTARABINE
BORTEZOMIB and CYTARABINE
CYTARABINE and VENETOCLAX

\*For more details of actionable molecular target(s) and pathway(s), please check this [link](#).

2. Patient Disease Characteristics: Key Biomarker(s)

PARP1	AURKB
CHEK2	TP53
CHEK1	PPARG
CSNK2A1	
MYC	

\*For more details on selected biomarker(s) and its impact on patient's disease profile, please check this [link](#).

3. Biomarker Impact Score

Therapies of Interest	Patient Biomarker Characteristics								Biomarker Impact Score
	PARP1	CHEK2	CHEK1	CSNK2A1	MYC	AURKB	TP53	PPARG	
AZACITIDINE+CYTARABINE	✓	✓	✓	✓	✓	✓	✓	✓	8 / 8
BORTEZOMIB+CYTARABINE	✓	✓	✓	✓	✓	✓	✓	✓	8 / 8
CYTARABINE+VENETOCLAX	✓	✓	✓	✓	✓	✓	✓		7 / 8

The Cellworks proprietary workflow solution used to generate this test report from patient's medical records (Test Report), has not been approved by any regulatory or medical authority. Cellworks generated information is adjunctive information to physicians and molecular tumor boards. CELLWORKS DOES NOT ASSURE OR GUARANTEE THE SUCCESS OF ANY THERAPEUTIC OPTION IDENTIFIED IN THIS TEST REPORT. The user of this Test Report remains responsible for the conduct of patient care and for evaluating the clinical relevance of information provided by the prediction software. Cellworks is not an entity licensed to practice medicine or clinical activity and the Test Report generated by Cellworks does not amount to, or substitute, qualified professional medical advice.



**VENTURA™**  
PRECISION MEDICINE

**Clinical ID:** ABC-12345

**Cellworks ID:** 444444

**Ref Physician:** Dr. John

**Biopsy Sequence:** 1


**Gender/Age:** - / -

**Date of Report:** 06th Aug 2018


**Indication: Myelodysplastic Syndrome(MDS)**

4. Predicted Drug Sensitivity or Resistance

4.1 Single Drug Efficacy Prediction



4.2 Drug Combination Efficacy Prediction





**VENTURA™**  
PRECISION MEDICINE

**Clinical ID:** ABC-12345

**Cellworks ID:** 444444

**Ref Physician:** Dr.John

**Biopsy Sequence:** 1

**Gender/Age:** - / -

**Date of Report:** 06th Aug 2018

**Indication: Myelodysplastic Syndrome(MDS)**

5. Summary of Patient Genomic Profile

Input Data Type	Mutations, CNV and Cytogenetics
Genetic Mutation(s)	5
Copy Number Variation(s)	373
Gene(s) Methylated	0

5.1 Detailed Information of Genomic Aberration(s) Modeled

5.1.1 Gene Mutation(s) with Gain of Function

NCOR1	PTPN11	TCF7L2
-------	--------	--------

5.1.2 Gene Mutation(s) with Loss of Function

KMT2C	MSH6
-------	------

5.1.3 Gene(s) with Increase in Copy Number Variation [CNV]

ABHD12	ABHD16A	ACSS1	ADRM1	AGER	ALG12	ANGPT1	ANGPT2
ARHGAP8	ASAHI	ASH2L	ATP6V1H	BAALC	BAG4	BIK	BLK
CCNE2	CDC25B	CEBPD	CERK	CHKB	CLU	CNOT7	COPS5
CSGALNACT1	CSNK2A1	CSNK2B	CTSB	CYP7A1	DDR1	DDX39B	DEPTOR
DERL1	DGATI	DHX16	DLC1	DPYS	E2F5	EGR3	EHMT2
EIF3E	EIF3H	EIF4EBP1	ELP3	EPHX2	ESRP1	EYA1	FABP5
FBXO32	FBXO43	FDFT1	FGFR1	FKBP1A	FKBPL	FNTA	FOXA2
GATA4	GFRA2	GFRA4	GGH	GPT	GSR	GTSE1	GZF1
HAS2	HDAC10	HEY1	HSF1	ID1	IDH3B	IDO1	IDO2
IKBKB	IL7	JAG1	KAT6A	LAMA5	LOXL2	LPL	LTA



**VENTURA™**  
PRECISION MEDICINE

**Clinical ID:** ABC-12345

**Cellworks ID:** 444444

**Ref Physician:** Dr. John

**Biopsy Sequence:** 1

**Gender/Age:** - / -

**Date of Report:** 06th Aug 2018

**Indication: Myelodysplastic Syndrome(MDS)**

LTB	LY96	LYN	LYPLA1	MAPK11	MAPK12	MAVS	MCM4
MDC1	MICA	MICB	MMP16	MTDH	MYC	NBN	NCOA2
NDRG1	NEIL2	NOTCH4	NRG1	NSFL1C	NSMAF	NUDT18	OPLAH
PAG1	PBK	PCNA	PDLIM2	PDP1	PIM3	PLAT	PLCB1
PLXNB2	POLB	POU5F1	PPARA	PPP2R2A	PREX2	PRKDC	PRNP
PRR5	PSMA7	PTDSS1	PTK2	PTK2B	PTP4A3	RAB2A	RAD21
RALGAPA2	RASSF2	RB1CC1	RBCK1	RGS19	RIPK2	RRM2B	RUNX1T1
SCO2	SCRIB	SDC2	SFRP1	SFTPC	SGK3	SIRPA	SLC23A2
SLC25A32	SLC2A4RG	SNAI2	SNAP25	SPTLC3	SQLE	SRXN1	ST3GAL1
STK3	TASP1	TCEA1	TNF	TNFRSF10A	TNFRSF10B	TNFRSF10C	TNFRSF10D
TNFRSF11B	TRIB3	TRIM26	TYMP	UBR5	WNT7B	WRN	XKR4
XKR9	YWHAZ	ZDHHC2	ZFPM2	ZNF703			

**5.1.4 Gene(s) with Decrease in Copy Number Variation [CNV]**

ABCB1	ABCB5	ACSS2	ACTB	ADA	ADCY1	ADCYAPIR1	AHCY
AHR	AKAP9	AKR1B10	ARPC1A	ASB4	ASL	ASNS	ATG9B
AURKA	B4GALT5	BAZ1B	BCL7B	BHLHA15	BLVRA	BRAF	CAMK2B
CARD11	CASP2	CAV1	CCL26	CD36	CD40	CDK5	CDK6
CEBPB	CHN2	CLDN4	CNOT4	COL1A2	COPS6	CREB3L2	CUL1
CUX1	CYCS	CYP24A1	CYP51A1	DAGLB	DBF4	DDC	DGKB
DGKI	DMTF1	DNAJB6	DNAJB9	DNMT3B	DOCK4	DSN1	E2F1
EGFR	EIF2S2	EIF3B	ELMO1	ELMO2	EPB41L1	EPHA1	EPHB4
EPHB6	EPO	ETV1	EXOC4	EZH2	FSCN1	FZD1	FZD9
GGCT	GGT7	GLI3	GRB10	GSS	GSTK1	GTF2I	HBP1
HDAC9	HGF	HIPK2	HNF4A	HNRNPA2B1	HOXA1	HOXA10	HOXA11



**VENTURA™**  
PRECISION MEDICINE

**Clinical ID:** ABC-12345

**Cellworks ID:** 444444

**Ref Physician:** Dr. John

**Biopsy Sequence:** 1

**Gender/Age:** - / -

**Date of Report:** 06th Aug 2018

**Indication: Myelodysplastic Syndrome(MDS)**

HOXA13	HOXA3	HOXA5	HOXA7	HOXA9	HSPB1	HTR5A	HUS1
IGFBP1	IGFBP3	IKZF1	IL6	IMPDH1	INSIG1	ITCH	ITGB8
L3MBTL1	LAMB1	LBP	LEP	LIMK1	MAD1L1	MAFB	MAFK
MAGI2	MCM7	MDH2	MET	MIOS	MIR182	MIR29A	MIR29B1
MLXIPL	MMP9	MNX1	MYBL2	NAMPT	NCF1	NCOA3	NCOA6
NDRG3	NFATC2	NOS3	NRF1	NUDT1	NUP205	OGDH	PAXIP1
PDGFA	PDIA4	PDK4	PHF20	PIK3CG	PLCG1	PMS2	PODXL
POLD2	POLM	PPP1R3A	PREX1	PRSS1	PSMA2	PSMC2	PSMG3
PSPH	PTGIS	PTN	PTPN1	PTPRZ1	RAC1	RALA	RASA4
RBL1	RHEB	RPA3	SAMHD1	SDC4	SEC61G	SEMA3E	SERPINE1
SFRP4	SH2B2	SHH	SLA2	SLC29A4	SMO	SMURF1	SNAI1
SNX13	SRC	SRPK2	STEAP1	STEAP4	STK4	STX1A	TBXAS1
TFPI2	TOP1	TRIM24	TWIST1	UBE3C	UPP1	USP42	VIPR2
WASL	WEE2	WIPI2	WISP2	XRCC2	ZC3HC1	ZDHHC4	ZNF217



**VENTURA™**  
PRECISION MEDICINE

**Clinical ID:** ABC-12345

**Cellworks ID:** 444444

**Ref Physician:** Dr. John

**Biopsy Sequence:** 1

**Gender/Age:** - / -

**Date of Report:** 06th Aug 2018

**Indication: Myelodysplastic Syndrome(MDS)**

6. Therapy Rationale(s)

Rationales provided in this section highlight the pathways connected to drug sensitivity and resistance and include references to supporting published literature.

Species in **red** denote drug impact points. Species highlighted in **blue** are the key biomarkers.

STATUS: **GOF:** Gain of Function Mutations; **LOF:** Loss of Function Mutations; **SOF:** Switch of Function Mutations; **AMP:** CNV Over-expression; **DEL:** CNV Knock-down;

TYPE: **R:** Resistant Gene/Loop for the Drug; **S:** Sensitive Gene/Loop for the Drug

AZACITIDINE				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
L3MBTL1	DEL	S	<b>AZACITIDINE</b> —  <b>DNMT1</b>	12154409 23671287 17540172 16357870 14532106 15824892 19363521 28928282 17015478 22024163
			L3MBTL1 —  E2F1 —> EZH2 —> <b>DNMT1</b> —> CPGMET	
			—  <b>TP53</b> —  CANCER PROGRESSION	
			L3MBTL1 —  E2F1 —> EZH2 —> <b>DNMT1</b> —> CPGMET	
			—  <b>CDKN1A</b> —  <b>CSNK2A1</b> —> API —> CTNNB1 —>	
			CANCER PROGRESSION	
KAT6A	AMP	S	<b>AZACITIDINE</b> —  <b>DNMT1</b> —> <b>CPGMET</b>	25772242 12154409 23671287 16357870 19363521 28928282 17015478 22024163 15824892
			KAT6A —> EZH2 —> DNMT1 —> <b>CPGMET</b> —  <b>TP53</b>	
			—  CANCER PROGRESSION	
			KAT6A —> EZH2 —> DNMT1 —> <b>CPGMET</b> —  <b>CDKN1A</b>	
			—  <b>CSNK2A1</b> —> API —> CTNNB1 —> CANCER	
			PROGRESSION	
L3MBTL1	DEL	S	L3MBTL1 —  E2F1 —> EZH2 —> <b>DNMT1</b> —> CPGMET	12154409 23671287 17540172 16357870 14532106 15824892 19363521 28928282 17015478 22024163
			—  <b>DUSP6</b> —  <b>MAPK1</b> —> <b>MYC</b> —> CANCER	
			PROGRESSION	
			L3MBTL1 —  E2F1 —> EZH2 —> <b>DNMT1</b> —> <b>CHEK1</b>	
			—> <b>AURKB</b> —> SP1 —> CANCER PROGRESSION	
			PROGRESSION	



**VENTURA™**  
PRECISION MEDICINE

**Clinical ID:** ABC-12345

**Cellworks ID:** 444444

**Ref Physician:** Dr. John

**Biopsy Sequence:** 1

**Gender/Age:** - / -

**Date of Report:** 06th Aug 2018

**Indication: Myelodysplastic Syndrome(MDS)**

AZACITIDINE				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
EZH2	DEL	R	<p><b>AZACITIDINE</b> —  DNMT1 —&gt; <b>CPGMET</b></p> <p>EZH2 —&gt; DNMT1 —&gt; <b>CPGMET</b> —  TP53 —  CANCER PROGRESSION</p> <p>EZH2 —&gt; DNMT1 —&gt; <b>CPGMET</b> —  CDKN1A —  CSNK2A1</p> <p>—&gt; API —&gt; CTNNB1 —&gt; CANCER PROGRESSION</p> <p>EZH2 —&gt; DNMT1 —&gt; <b>CPGMET</b> —  DUSP6 —  MAPK1</p> <p>—&gt; MYC —&gt; CANCER PROGRESSION</p> <p>EZH2 —&gt; DNMT1 —&gt; CHEK1 —&gt; AURKB —&gt; SP1 —&gt; CANCER PROGRESSION</p>	<p>12579297 12154409</p> <p>16357870 19363521</p> <p>28928282 17015478</p> <p>22024163 15824892</p>
GGH	AMP	R	<p><b>AZACITIDINE</b> —  DNMT1 —&gt; <b>CPGMET</b></p> <p>GGH —  S ADENOSYL METHIONINE —&gt; <b>CPGMET</b> —  TP53 —  CANCER PROGRESSION</p> <p>GGH —  S ADENOSYL METHIONINE —&gt; <b>CPGMET</b> — </p> <p>CDKN1A —  CSNK2A1 —&gt; API —&gt; CTNNB1 —&gt; CANCER PROGRESSION</p> <p>GGH —  S ADENOSYL METHIONINE —&gt; <b>CPGMET</b> — </p> <p>DUSP6 —  MAPK1 —&gt; MYC —&gt; CANCER PROGRESSION</p>	<p>12154409 23671287</p> <p>25502219 25224413</p> <p>19363521 28928282</p>



**VENTURA™**  
PRECISION MEDICINE

**Clinical ID:** ABC-12345

**Cellworks ID:** 444444

**Ref Physician:** Dr. John

**Biopsy Sequence:** 1

**Gender/Age:** - / -

**Date of Report:** 06th Aug 2018

**Indication: Myelodysplastic Syndrome(MDS)**

BORTEZOMIB				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
MYC	AMP	S	<p><b>BORTEZOMIB</b> —  <b>PROTEASOME</b> —  <b>ER STRESS</b> —&gt; <b>ATF4</b></p> <p>—&gt; <b>DDIT4</b> —  <b>MTOR</b> —&gt; <b>MYC</b></p> <p><b>MYC</b> —&gt; CANCER PROGRESSION</p>	<p>22685320 23612979</p> <p>26327694 21247388</p>
CDK5	DEL	S	<p><b>BORTEZOMIB</b> —  <b>PROTEASOME</b> —  <b>ER STRESS</b></p> <p>CDK5 —&gt; NFE2L2 —&gt; PSMB5 —&gt; <b>PROTEASOME</b> —  <b>ER STRESS</b></p>	<p>21247388 21289309</p> <p>27169614</p>
EZH2	DEL	S	<p><b>BORTEZOMIB</b> —  <b>PROTEASOME</b> —  <b>ER STRESS</b> —&gt; <b>ATF4</b></p> <p>—&gt; <b>DDIT3</b> —&gt; <b>BCL2L11</b> —  <b>BCL2</b></p> <p>EZH2 —&gt; PRC2_COMPLEX —&gt; H3K27 METHYLATION — </p> <p><b>BCL2</b> —&gt; CANCER PROGRESSION</p>	<p>21247388 16357870</p> <p>26472914 21841772</p> <p>24177192</p>





**VENTURA™**  
PRECISION MEDICINE

**Clinical ID:** ABC-12345

**Cellworks ID:** 444444

**Ref Physician:** Dr. John

**Biopsy Sequence:** 1

**Gender/Age:** - / -

**Date of Report:** 06th Aug 2018

**Indication: Myelodysplastic Syndrome(MDS)**

CYTARABINE				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
PMS2	DEL	S	<p><b>CYTARABINE</b> → <b>DNA DAMAGE</b></p> <p>PMS2 → DNA REPAIR (MMR) → <b>DNA DAMAGE</b></p>	19793570 28347324 11292842 23361057 2311169
MSH6	LOF	S	<p><b>CYTARABINE</b> → <b>DNA DAMAGE</b></p> <p>MSH2 → DNA REPAIR (MMR) → <b>DNA DAMAGE</b></p>	27869523 23361057
KMT2C	LOF	S	<p><b>CYTARABINE</b> → <b>DNA DAMAGE</b></p> <p>KMT2C → H3K4_METHYLATION → MLH1 → DNA REPAIR (MMR) → <b>DNA DAMAGE</b></p>	2311169 24403070 15475387 25135975 25043185 23361057
HUS1	DEL	S	<p><b>CYTARABINE</b> → <b>DNA DAMAGE</b></p> <p>HUS1 → DNA REPAIR (MMR) → <b>DNA DAMAGE</b></p>	20188637 23361057 2311169 15314187
MYC	AMP	R	<p><b>CYTARABINE</b> → <b>DNA DAMAGE</b></p> <p>MYC → DHODH → dCTP → <b>DNA DAMAGE</b></p> <p>MYC → CTPS → dCTP → <b>DNA DAMAGE</b></p> <p>→ <b>CYTARABINE</b> → <b>DNA DAMAGE</b></p>	2311169 18628958 23361057 25127121



**VENTURA™**  
PRECISION MEDICINE

**Clinical ID:** ABC-12345

**Cellworks ID:** 444444

**Ref Physician:** Dr. John

**Biopsy Sequence:** 1

**Gender/Age:** - / -

**Date of Report:** 06th Aug 2018

**Indication:** Myelodysplastic Syndrome(MDS)

VENETOCLAX				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
EZH2	DEL	S	<p><b>VENETOCLAX</b> —  <b>BCL2</b></p> <p>EZH2 —&gt; PRC2 COMPLEX —&gt; H3K27 TRIMETHYLATION — </p> <p><b>BCL2</b> —&gt; CANCER PROGRESSION</p> <p>EZH2 —&gt; PRC2 COMPLEX —&gt; H3K27 TRIMETHYLATION — </p> <p>HOXA9 —&gt; <b>BCL2</b> —&gt; CANCER PROGRESSION</p>	27252989 22508723 26472914 24987060 24177192
PLCB1	AMP	S	<p><b>VENETOCLAX</b> —  <b>BCL2</b></p> <p>PLCB1 —&gt; PRKCA —&gt; <b>BCL2</b> —&gt; CANCER PROGRESSION</p>	29707107 18670360 14737078
MYC	AMP	R	<p><b>VENETOCLAX</b> —  <b>BCL2</b></p> <p><b>MYC</b> —  <b>BCL2</b> —&gt; CANCER PROGRESSION</p>	23291630 24506200 11704823



**VENTURA™**  
PRECISION MEDICINE

**Clinical ID:** ABC-12345

**Cellworks ID:** 444444

**Ref Physician:** Dr. John

**Biopsy Sequence:** 1

**Gender/Age:** - / -

**Date of Report:** 06th Aug 2018

**Indication: Myelodysplastic Syndrome(MDS)**

7. Genomic Aberration to Key Biomarker Pathway(s)

This section provides a snapshot of paths connecting the most significant gene aberrations with patient biomarkers and references to published research supporting these pathways.

**RED:** Gain of Function/Switch of Function Mutation(s) or Amplified Gene(s)

**BLUE:** Loss of Function Mutation(s) or Deleted Gene(s)

TRANSCRIPTION FACTORS:

Key Biomarker(s)	Molecular Pathway Rationale for Biomarker(s)	Reference PMID(s)
MYC		10373534 10550055 10783165 10866324 11255227 12149649 14701743 18438430 22319212 22850745 25101980 2663470 9788437
		17540172
		28729862
TP53		10373534 10550055 10783165 10866324 14701743 19377469 22319212 9582019
		19433796 22034226
PPARG		10373534 10550055 10783165 10866324 11255227 12479814 14701743 15832170 16127449 22319212 22850745 25101980 9030579
		16029943



**VENTURA™**  
PRECISION MEDICINE

**Clinical ID:** ABC-12345

**Cellworks ID:** 444444

**Ref Physician:** Dr. John

**Biopsy Sequence:** 1

**Gender/Age:** - / -

**Date of Report:** 06th Aug 2018

**Indication: Myelodysplastic Syndrome(MDS)**

KINASE\*\*:

Key Biomarker(s)	Molecular Pathway Rationale for Biomarker(s)	Reference PMID(s)
CSNK2A1	CUX1 → ATM → BRCA1 → CDKN1A — CSNK2A1	10373534 10550055 10783165 10866324 11255227 14701743 22319212 22850745 25101980
AURKB	CUX1 → ATM → BRCA1 → CDKN1A — CSNK2A1 → HDAC3 → AURKB	10373534 10550055 10783165 10866324 11255227 14701743 19287963 22319212 22751009 22850745 25101980

\*\* Assayable key kinase biomarkers identified for this patient.



**VENTURA™**  
**PRECISION MEDICINE**

**Clinical ID:** ABC-12345

**Cellworks ID:** 444444

**Ref Physician:** Dr. John

**Biopsy Sequence:** 1

**Gender/Age:** - / -

**Date of Report:** 06th Aug 2018

**Indication: Myelodysplastic Syndrome(MDS)**

8. Terms of Usage

Cellworks Therapeutic Solutions

The Cellworks proprietary workflow solution used to generate this test report from patient's medical records (Test Report), has not been approved by any regulatory or medical authority. Cellworks generated information is adjunctive information to physicians and molecular tumor boards. CELLWORKS DOES NOT ASSURE OR GUARANTEE THE SUCCESS OF ANY THERAPEUTIC OPTION IDENTIFIED IN THIS TEST REPORT. The therapeutic options provided in the Test Report are not ranked in order of efficacy, safety or cost-effectiveness and are sorted based on our model's analysis of the input data. All individual drugs included in therapy options identified in the Test Report have been cleared and approved by the United States Food and Drug Administration (FDA) for other indications. At the specific request of the patient or treating physician, the Test Report may identify drugs or therapy options that are also in an advanced stage of clinical trials and yet to be approved. This will provide adjunctive information to the physicians for selecting a clinical trial for the patient.

Therapeutic agents associated with potential benefit or lack of benefit, as indicated in the Test Report are based on biomarker results provided in the report and on published evidence with PMID references. This evidence in some cases may have been obtained from studies performed in the cancer type present in the tested patient's sample.

No Guarantee of Clinical Benefit

The finding of a biomarker expression does not necessarily indicate pharmacologic effectiveness or lack thereof. The agents identified may or may not be suitable for use with a particular patient and the Test Report does not guarantee or suggest that any particular agent will be effective with the treatment of any particular condition. The user of this Test Report remains responsible for the conduct of patient care and for evaluating the clinical relevance of information provided by the prediction software.

Intended Use

Cellworks is not an entity licensed to practice medicine or clinical activity and the Test Report generated by Cellworks does not amount to, or substitute, qualified professional medical advice. THIS REPORT IS PREPARED AS ADJUNCTIVE INFORMATION TO ASSIST HEALTH CARE PROVIDERS TO EVALUATE THEIR PATIENTS. CELLWORKS IS NOT RESPONSIBLE FOR ANY USE OF THIS TEST REPORT OR DATA BY ANY UNQUALIFIED PERSON. Decisions on patient care and treatment, including safety and security of treatments based on this Test Report must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition and the treatment should not solely be based on this Test Report. Cellworks provides no guarantee of the accuracy, relevance, exhaustiveness or appropriateness of any of the medical information referenced through this Test Report.

CELLWORKS DISCLAIMS ALL WARRANTIES, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF TITLE, NON- INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, IN RELATION TO INTERFACE, ITS SERVICES AND THE TEST REPORT. CELLWORKS PROVIDES NO ASSURANCE OR GUARANTEE THAT A HEALTHCARE PROVIDER, INSURER OR ANY OTHER THIRD PARTY PAYOR, WHETHER GOVERNMENTAL OR PRIVATE, WILL REIMBURSE A PATIENT FOR THE COST OF GENERATING TEST REPORT.

This is an automatically generated report. No signature is required.  
--END OF THE REPORT--